Share this article
Share this article
HORSHAM, Pa., May 21, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANT
TM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
1 RYBREVANT
TM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.
Share:
HANGZHOU, China and NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) AnHeart Therapeutics Co., Ltd. ( AnHeart ), a clinical stage oncology company focused on underserved patients in global markets, announces an upcoming presentation of an abstract selected for poster presentation from its ongoing Phase II trial of taletrectinib in ROS1 fusion positive Non-Small Cell Lung Cancer (NSCLC) (NCT04395677) at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually on June 4-8, 2021. Details on the abstract and a corresponding poster presentation are shown below.
Abstract Number: 9066
Abstract Title:
Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.
Findings to be presented at the ASCO Annual Meeting show preliminary efficacy in patients with EGFR-mutated NSCLC and Janssen's commitment to address the need for new targeted therapies for this patient
AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.